disease (ad)

Aducanumab (BIIB037), A selective human immunoglobulin gamma-1 (IgG1) monoclonal antibody, targets the clustered form of amyloid beta (Aβ). Aducanumab shows brain permeability and may be used to treat Alzheimer's disease (AD).

Bapineuzumab (AAB-001) is a humanised monoclonal antibody targeting amyloid-beta (Aβ), capable of binding to the N-terminal region of both soluble and oligomeric forms of amyloid β, and is used for research into Alzheimer's disease (AD).

Bepranemab (UCB 0107) is a humanized anti-tau monoclonal antibody of the IgG class for the study of Alzheimer's disease (AD) and tau protein disorders.

Gosuranemab (BIIB092) is a humanised monoclonal antibody targeting N-terminal tau, inhibiting the propagation and aggregation of pathological tau proteins for potential application in Alzheimer's disease.

Lecanemab (BAN-2401) is an IgG1 monoclonal antibody targeting soluble aggregated β-amyloid (Abeta) with activity against oligomers, protofibrils, and insoluble protofibrils, and may be useful in the study of Alzheimer's disease (AD)-induced mild cognitive impairment and mild AD dementia.

Vanutide cridificar (ACC-001) is an aminoterminal Aβ1-7 peptide conjugate used in Alzheimer's disease (AD) research [1].

APNmAb005 is a human monoclonal antibody (mAb) that targets MAPT/Tau/PHF-tau. It can inhibit tau seeding in vitro and prevent neuronal loss in rTG4510 mice. APNmAb005 is applicable for Alzheimer's disease (AD) research.

E2814 is a human monoclonal antibody (mAb) that specifically targets MAPT/Tau. It is applicable for passive immunization studies in Alzheimer's disease (AD).

TBL-100 is a human monoclonal antibody (mAb) that targets Tau. It is applicable for research in Alzheimer's disease (AD) and progressive supranuclear palsy.

TB-006 is a human monoclonal antibody (mAb) that targets Galectin-3. It is applicable in Alzheimer's disease (AD) research. The recommended isotype control is Human IgG1 kappa.

ZEB85 is a human monoclonal antibody (mAb) that targets TrkB. It activates TrkB and its downstream signaling cascade, enhancing neuronal activity. ZEB85 can prevent β-amyloid toxicity in cultured hippocampal neurons and is useful for Alzheimer's disease (AD) research.

Aducanumab (Mouse IGG2a) is a monoclonal antibody that selectively targets aggregated amyloid-beta protein (Aβ). Its variable region matches that of Aducanumab, while the constant region is derived from the Mouse IGG2a sequence. Aducanumab (Mouse IGG2a) demonstrates strong selectivity for Aβ fibrils, with EC50 values of >1 μM for Aβ1-40 monomer and 0.2 nM for Aβ1-42 fibrils. This compound can be utilized in Alzheimer's disease (AD) research.

BIIB076 is a human monoclonal antibody (mAb) that targets PHF-tau. It is utilized in passive immunization studies for Alzheimer's disease (AD).